

Retisert® (fluocinolone acetonide intravitreal implant)



When requesting Retisert® (fluocinolone acetonide intravitreal implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication

- Retisert® (fluocinolone acetonide intravitreal implant) is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Coverage Guidelines

The individual must meet all of the following criteria for approval:

- Diagnosis of chronic non-infectious uveitis affecting the posterior segment of the eye.
- Does not have an active viral, bacterial, mycobacterial or fungal infection of ocular structures

Approval duration: 30 months

Dosing Recommendations

- 0.59 mg intravitreal implant. It will release 0.6 µg/day, decreasing over the first month to a steady state between 0.3-0.4 µg/day over approximately 30 months.

References

1. Iluvien® prescribing information. Alpharetta, GA: Alimera Sciences, Inc.: May 20
2. Fluocinolone acetonide. In: DRUGDEX® System. Micromedex 2.0. Greenwood Village, CO; Thompson Reuters (Healthcare). [Accessed April 17, 2018].